# MB Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mb-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Montpellier, France
- Website: www.mb-therapeutics.com
- Total disclosed funding: $1M
- Latest round: Seed (Feb 24, 2025)
- Investors on record: 4

## About

MB Therapeutics focuses on innovative healthcare 3D printing technologies to deliver personalized medicine solutions, enhancing treatment adherence and clinical trial efficiency.Founded in 2023, MB Therapeutics operates in Montpellier, France, specializing in the development of personalized medicine through 3D printing technologies. The company has completed one deal to date, raising EUR 2 million in Seed funding on February 24, 2025, led by Beprep alongside investors such as Angels Santé, Bpifrance, and Calyseed. The founder's previous ventures are not publicly documented.MB Therapeutics specializes in healthcare 3D printing technologies aimed at developing personalized medicine solutions. Their core offerings focus on the customization of medication, which includes tailored dosages, unique drug forms, and the ability to integrate multiple active ingredients into singular treatments. These innovations enhance treatment adherence, improve patient outcomes, and streamline clinical trials by allowing on-demand medication delivery directly at clinical sites. Their client base primarily includes pharmaceutical companies and healthcare providers in European and North American markets, aiming to improve patient care through advanced pharmaceutical technologies. The company adheres to Good Manufacturing Practices (GMP) to ensure compliance with industry standards.MB Therapeutics generates revenue through direct collaborations with pharmaceutical companies and healthcare providers, emphasizing B2B transactions. Their revenue model includes partnerships that allow clients to access their innovative 3D printing technologies for personalized drug manufacturing. Transactions typically revolve around project-based agreements where clients engage MB Therapeutics for the development and production of customized medications tailored to specific patient needs. The pricing structure reflects the complexity and customization of services rendered, aligning costs with the unique demands of each project. Flagship offerings such as their proprietary 3D printing systems are central to these agreements, highlighting the strategic partnerships formed to enhance medication delivery and patient care.In February 2025, MB Therapeutics raised EUR 2 million in Seed funding led by Beprep, with participation from Angels Santé, Bpifrance, and Calyseed. The funding will be utilized to industrialize and launch a solution for personalized medicine manufacturing in pharmacies. The company intends to introduce new products aimed at further enhancing their 3D printing capabilities, targeting expansion into additional geographic markets in Europe and North America by the end of 2025.

## Funding rounds

- Seed, Feb 24, 2025, $1M — Bpifrance, Angels Santé, BEPREP, Calyseed

## Investors

- Bpifrance — Seed
- Angels Santé (https://capitalatlas.ai/funds/angels-sante) — Seed
- BEPREP — Seed
- Calyseed — Seed